- ISIN
- US69353Y1038
- CUSIP
- 69353Y103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 25, 2020
Highlights
- Market Cap
- $64.53M
- Enterprise Value
- $25.99M
- EPS (TTM)
- -$1.48
- Gross Profit (TTM)
- -$97.00K
- EBITDA (TTM)
- -$80.43M
- Year Range
- $0.96 - $1.88
- Target Price
- $18.00
- ROA (TTM)
- -81.13%
- ROE (TTM)
- -89.06%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PMVP Performance Chart
PMV Pharmaceuticals, Inc. (PMVP) is down 3.2% since the beginning of the year. At $1 per share, PMVP is trading 35.6% below its 52-week high of $2. Investors who bought $1,000 worth of PMVP shares 5 years ago would now be looking at an investment worth $38.
Loading charts...
Returns By Period
PMV Pharmaceuticals, Inc. (PMVP) has returned -3.20% so far this year and 13.08% over the past 12 months.
PMV Pharmaceuticals, Inc.
- 1D
- 6.14%
- 1M
- -3.97%
- YTD
- -3.20%
- 6M
- -0.41%
- 1Y
- 13.08%
- 3Y*
- -40.86%
- 5Y*
- -48.11%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
PMVP Monthly Returns History
Based on dividend-adjusted daily data since Sep 25, 2020, PMVP's average daily return is -0.11%, while the average monthly return is -1.93%.
Historically, 40% of months were positive and 60% were negative. The best month was Dec 2020 with a return of +74.6%, while the worst month was Oct 2023 at -75.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, PMVP closed higher 46% of trading days. The best single day was Nov 1, 2023 with a return of +31.1%, while the worst single day was Oct 12, 2023 at -47.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -13.60% | 57.41% | -27.06% | 12.10% | -13.67% | 0.83% | -3.20% | ||||||
| 2025 | -5.96% | -3.52% | -20.44% | -9.17% | -11.29% | 20.70% | 33.96% | -1.41% | -0.00% | 0.71% | -6.38% | -5.30% | -17.22% |
| 2024 | -43.23% | 5.11% | -8.11% | 5.88% | 1.11% | -10.99% | 2.47% | -5.42% | -5.10% | 9.40% | -0.61% | -6.79% | -51.29% |
| 2023 | -5.75% | -12.07% | -33.84% | -3.35% | 16.05% | 17.01% | 4.47% | 10.40% | -14.96% | -75.41% | 51.66% | 35.37% | -64.37% |
| 2022 | -30.48% | -1.37% | 31.44% | -30.40% | -18.84% | 21.17% | 4.91% | -6.89% | -14.51% | 3.45% | -18.93% | -12.83% | -62.34% |
| 2021 | -44.50% | 10.22% | -12.60% | 2.55% | 1.99% | -0.70% | -0.44% | -10.76% | -1.81% | -20.74% | -7.92% | 6.21% | -62.45% |
Benchmark Metrics
PMV Pharmaceuticals, Inc. has an annualized alpha of -37.09%, beta of 1.16, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since September 25, 2020.
- This stock participated in 223.48% of S&P 500 Index downside but only 1.68% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -37.09%
- Beta
- 1.16
- R²
- 0.06
- Upside Capture
- 1.68%
- Downside Capture
- 223.48%
Return for Risk
Risk / Return Rank
PMVP ranks 51 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for PMV Pharmaceuticals, Inc. (PMVP) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PMVP | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.60 | ||
| Sortino ratioReturn per unit of downside risk | -1.59 | ||
| Omega ratioGain probability vs. loss probability | 1.10 | 1.32 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | 0.32 | 2.46 | -2.14 |
| Martin ratioReturn relative to average drawdown | 0.61 | 10.92 | -10.31 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the PMV Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the PMV Pharmaceuticals, Inc. was 98.64%, occurring on May 15, 2025. The portfolio has not yet recovered.
The current PMV Pharmaceuticals, Inc. drawdown is 98.03%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -98.64%May 2025 | 4y 4mo | — | 5y 5moJan 2021 - now |
2020 correction2020 | -16.16%Nov 2020 | 1mo 20d | 14d | 2mo 4dSep 2020 - Dec 2020 |
2020 correction2020 | -12.65%Dec 2020 | 4d | 3d | 7dDec 2020 - Dec 2020 |
2020 pullback2020 | -6.51%Dec 2020 | 2d | 2d | 4dDec 2020 - Dec 2020 |
2020 pullback2020 | -6.44%Dec 2020 | 1d | 7d | 8dDec 2020 - Dec 2020 |
Drawdown Indicators
| PMVP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.64% | -56.78% | -41.86% |
Max Drawdown (1Y)Largest decline over 1 year | -41.67% | -9.10% | -32.57% |
Max Drawdown (3Y)Largest decline over 3 years | -90.61% | -18.90% | -71.71% |
Max Drawdown (5Y)Largest decline over 5 years | -97.71% | -25.43% | -72.28% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -98.03% | -3.21% | -94.82% |
Average DrawdownAverage peak-to-trough decline | -79.87% | -10.71% | -69.16% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.51% | 2.04% | +19.47% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of PMV Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how PMV Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PMVP in comparison with other companies in the Biotechnology industry. Currently, PMVP has a P/B value of 0.7. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PMVP
Add PMV Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PMVP